Patent application number | Description | Published |
20090042223 | METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS - Methods and reagents are disclosed for enhancing the bioavailability of a hydrophobic drug, and in some embodiments for determining a hydrophobic drug, in a sample suspected of containing a hydrophobic drug. A combination is formed in a medium where the combination comprises the sample, a hemolytic agent where a determination of the hydrophobic drug is conducted, and a bioavailability agent for the hydrophobic drug. The bioavailability agent comprises an ionic detergent comprising a chain of at least 10 carbon atoms or a non-ionic detergent comprising a chain of at least 15 repeating ethylene oxide units or propylene oxide units or a combination of ethylene oxide units and propylene oxide units. The concentration of the bioavailability agent in the medium is sufficient to enhance the bioavailability of the hydrophobic drug. The medium is incubated under conditions for enhancing the bioavailability of the hydrophobic drug, and in a determination of the hydrophobic drug under conditions for hemolyzing cells in the sample. For determination of the hydrophobic drug, reagents for determining the presence and/or amount of the hydrophobic drug in the sample are added to the medium. The reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug. The presence and/or amount of the complex indicates the presence and/or amount of the hydrophobic drug in the sample. | 02-12-2009 |
20100297670 | METHODS FOR DETECTION OF IMMUNOSUPPRESSANT DRUGS - Methods and reagents are disclosed for enhancing the bioavailability of a hydrophobic drug, and in some embodiments for determining a hydrophobic drug, in a sample suspected of containing a hydrophobic drug. A combination is formed in a medium where the combination comprises the sample, a hemolytic agent where a determination of the hydrophobic drug is conducted, and a bioavailability agent for the hydrophobic drug. The bioavailability agent comprises an ionic detergent comprising a chain of at least 10 carbon atoms or a non-ionic detergent comprising a chain of at least 15 repeating ethylene oxide units or propylene oxide units or a combination of ethylene oxide units and propylene oxide units. The concentration of the bioavailability agent in the medium is sufficient to enhance the bioavailability of the hydrophobic drug. The medium is incubated under conditions for enhancing the bioavailability of the hydrophobic drug, and in a determination of the hydrophobic drug under conditions for hemolyzing cells in the sample. For determination of the hydrophobic drug, reagents for determining the presence and/or amount of the hydrophobic drug in the sample are added to the medium. The reagents comprise at least one antibody for the hydrophobic drug. The medium is examined for the presence of a complex comprising the hydrophobic drug and the antibody for the hydrophobic drug. The presence and/or amount of the complex indicates the presence and/or amount of the hydrophobic drug in the sample. | 11-25-2010 |
Patent application number | Description | Published |
20080268036 | Co-processing of active pharmaceutical/nutraceutical ingredients - A process for preparing agglomerated particles comprising a) preparing a slurry of a pre-manufactured agglomerated particles consisting of microcrystalline cellulose and one or more compressibility augmenting agents, and an active ingredient; and b) drying the slurry to form active agent agglomerated particles. | 10-30-2008 |
20100215753 | Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose - A solid dosage form is provided which includes an active agent and silicified microcrystalline cellulose, the dosage form formed by a) combining a wetted active agent with dry silicified microcrystalline cellulose in a dryer to form agglomerated particles; and b) incorporating the agglomerated particles into the solid dosage form. In certain preferred embodiments, step b comprises combining said silicified microcrystalline cellulose, said active agent, and colloidal silicon dioxide in a dryer. Preferably, the dryer is a spray dryer, and, in certain embodiments, the active agent may be an herbal extract. | 08-26-2010 |
20100285164 | Orally Disintegrating Excipient - The present invention is directed to coprocessed excipient particles comprising a cellulosic material such as microcrystalline cellulose in intimate association with silicon dioxide, a disintegrant and a polyol, sugar or a polyol/sugar blend. The excipient particles display good processing and are useful in prepared compressed solid dosage forms that exhibit rapid disintegration (less than about 60 seconds) when placed on the tongue or when tested according to USP disintegration testing, while still providing acceptable mouth feel. | 11-11-2010 |
Patent application number | Description | Published |
20130315549 | SPLICE CASSETTES AND CHIPS - A splice cassette includes a base and a cover. The base includes an outer channel and an inner storage region separated by a spool wall. The cover is configured to mount to the base to enclose the inner storage region. The outer channel extends radially outwardly from a perimeter of the cover. The cover includes guide spools and a chip receiving arrangement disposed on an inwardly-facing surface that faces the base when the cover mounts to the base. The splice chip remains on the cover when the cover is removed from the base. | 11-28-2013 |
20140086534 | RUGGEDIZED MULTI-FIBER FIBER OPTIC CONNECTOR WITH SEALED DUST CAP - A fiber optic connector and fiber optic cable assembly is disclosed. The assembly includes a fiber optic cable having a plurality of optical fibers. The assembly also includes a connector body, a multi-fiber ferrule and a protective housing. The fiber optic cable is anchored to a proximal end of the connector body and the multi-fiber ferrule is mounted at a distal end of the connector body. The multi-fiber ferrule supports end portions of optical fibers of the optical fiber cable. The protective housing mounts over the connector body. A dimensionally recoverable sleeve prevents contaminants from entering the protective housing through a proximal end of the protective housing. A dust cap and sealing member prevent contaminants from entering the protective housing through a distal end of the protective housing. | 03-27-2014 |
20150241639 | RUGGEDIZED MULTI-FIBER FIBER OPTIC CONNECTOR WITH SEALED DUST CAP - A fiber optic connector and fiber optic cable assembly is disclosed. The assembly includes a fiber optic cable having a plurality of optical fibers. The assembly also includes a connector body, a multi-fiber ferrule and a protective housing. The fiber optic cable is anchored to a proximal end of the connector body and the multi-fiber ferrule is mounted at a distal end of the connector body. The multi-fiber ferrule supports end portions of optical fibers of the optical fiber cable. The protective housing mounts over the connector body. A dimensionally recoverable sleeve prevents contaminants from entering the protective housing through a proximal end of the protective housing. A dust cap and sealing member prevent contaminants from entering the protective housing through a distal end of the protective housing. | 08-27-2015 |
20160004016 | OPTICAL FIBER CONNECTOR FOR MULTI-FIBER CABLE - Optical connector arrangements terminate at least seventy-two optical fibers. The optical connector arrangements include multiple optical ferrules that each terminates multiple optical fibers. Some example optical connectors can terminate about 144 optical fibers. Each optical connector includes a fiber take-up arrangement and a flange extending outwardly from a connector housing arrangement. The fiber take-up arrangement manages excess length of the optical fibers. A threadable coupling nut can be disposed on the connector housing arrangement to engage the outwardly extending flange. Certain types of optical connector arrangements include furcation cables spacing the connector housing arrangement form the fiber take-up arrangement. | 01-07-2016 |
20160004018 | OPTICAL FERRULE FOR MULTI-FIBER CABLE AND HARDENED MULTI-FIBER OPTIC CONNECTOR THEREFORE - A fiber optic cable assembly includes a fiber optic cable and a fiber optic connector. The cable includes a jacket, optical fibers, and strength components. The fiber optic connector holds at least two multi-fiber ferrules. Certain types of connectors include a connector body defining a side opening that extends along a length of the connector body; and a cover that mounts over the side opening. The fiber optic connector is hardened so that the fiber optic connector can ruggedizedly connect to a hardened fiber optic adapter arrangement. | 01-07-2016 |
20160103289 | SLIDABLE TELECOMMUNICATIONS TRAY WITH CABLE SLACK MANAGEMENT - A fiber optic telecommunications device includes a rack for mounting a plurality of chassis, each chassis including a plurality of trays slidably mounted thereon and arranged in a vertically stacked arrangement. Each tray includes fiber optic connection locations and a cable manager coupled to the tray and also coupled to the chassis, the cable manager for routing cables to and from the fiber optic connection locations and defining a plurality of link arms pivotally connected such that the manager retracts and extends with a corresponding movement of the tray, wherein the link arms pivot relative to each other to prevent cables managed therein from being bent in an arc having a radius of curvature less than a predetermined value, each link arm defining a top wall, a bottom wall, and two oppositely positioned sidewalls, each link arm defining an open portion along at least one of the sidewalls and an open portion along the top wall for receiving cables therein, the open portions along the top wall and the at least one of the sidewalls communicating with each other. | 04-14-2016 |
Patent application number | Description | Published |
20110079941 | Method of fabricating an implantable medical device with biaxially oriented polymers - Methods and systems for manufacturing an implantable medical device, such as a stent, from a tube with desirable mechanical properties, such as improved circumferential strength and rigidity, are described herein. Improved circumferential strength and rigidity may be obtained by inducing molecular orientation in materials for use in manufacturing an implantable medical device. Some embodiments may include inducing molecular orientation by expansion of a molten annular polymer film. Other embodiments may include inducing circumferential molecular orientation by inducing circumferential flow in a molten polymer. In certain embodiments, circumferential orientation may be induced by expansion of a polymer tube. Further embodiments may include manufacturing an implantable medical device from a biaxially oriented planar polymer film. | 04-07-2011 |
20120217672 | METHOD OF FABRICATING AN IMPLANTABLE MEDICAL DEVICE WITH BIAXIALLY ORIENTED POLYMERS - Methods and systems for manufacturing an implantable medical device, such as a stent, from a tube with desirable mechanical properties, such as improved circumferential strength and rigidity, are described herein. Improved circumferential strength and rigidity may be obtained by inducing molecular orientation in materials for use in manufacturing an implantable medical device. Methods of inducing circumferential molecular orientation by inducing circumferential flow in a molten polymer are disclosed. | 08-30-2012 |
20140107761 | Biodegradable stent with enhanced fracture toughness - Stents and methods of manufacturing a stents with enhanced fracture toughness are disclosed. | 04-17-2014 |
20140107762 | Biodegradable stent with enhanced fracture toughness - Stents and methods of manufacturing a stents with enhanced fracture toughness are disclosed. | 04-17-2014 |
20140114394 | Biodegradable stent with enhanced fracture toughness - Stents and methods of manufacturing a stents with enhanced fracture toughness are disclosed. | 04-24-2014 |
20140128959 | Biodegradable stent with enhanced fracture toughness - Stents and methods of manufacturing a stents with enhanced fracture toughness are disclosed. | 05-08-2014 |
Patent application number | Description | Published |
20090005733 | INFUSION TREATMENT AGENTS, CATHETERS, FILTER DEVICES, AND OCCLUSION DEVICES, AND USE THEREOF - Embodiments include an infusion-occlusion system having a delivery catheter, a guide catheter adapted to receive the delivery catheter, and a guidewire with an occlusion device adapted to be received within the guide catheter. The guide catheter of the catheter kit may be provided with an occlusion device at the distal end of the guide catheter. The delivery catheter may have an accessory lumen, coaxial or co-linear lumen, a supporting mandrel, or an occlusion device at its distal end. Moreover, according to some embodiments, occlusion devices may be a single material or a composite balloon having an inner liner and an outer layer of different materials, a high compliance low pressure balloon, or a filter device that restricts particles from passing through but does not restrict fluid, such as blood. An inflation device with a large volume and low volume syringe can be used to inflate the balloon. | 01-01-2009 |
20090018498 | INFUSION TREATMENT AGENTS, CATHETERS, FILTER DEVICES, AND OCCLUSION DEVICES, AND USE THEREOF - Embodiments include an infusion-occlusion system having a delivery catheter, a guide catheter adapted to receive the delivery catheter, and a guidewire with an occlusion device adapted to be received within the guide catheter. The guide catheter of the catheter kit may be provided with an occlusion device at the distal end of the guide catheter. The delivery catheter may have an accessory lumen, coaxial or co-linear lumen, a supporting mandrel, or an occlusion device at its distal end. Moreover, according to some embodiments, occlusion devices may be a single material or a composite balloon having an inner liner and an outer layer of different materials, a high compliance low pressure balloon, or a filter device that restricts particles from passing through but does not restrict fluid, such as blood. An inflation device with a large volume and low volume syringe can be used to inflate the balloon. | 01-15-2009 |
Patent application number | Description | Published |
20140030748 | METHOD AND SYSTEM TO MANAGE DIABETES USING MULTIPLE RISK INDICATORS FOR A PERSON WITH DIABETES - Described are methods and systems to annunciate to the patient of the components involved in each of the daily risk range based on the glucose measurements to assist the patient in identification of whether it is hypoglycemia or hyperglycemia are driving the daily risk range of the measured glucose values. | 01-30-2014 |
20140081103 | METHOD AND SYSTEM TO DERIVE GLYCEMIC PATTERNS FROM CLUSTERING OF GLUCOSE DATA - Described are methods and systems for determining clusters of glucose data that can be utilized to provide insights to the person with diabetes, such as, for example, when a certain number of measurements during a predetermined time period is less than a predetermined threshold so that the subject is notified that the number of glucose measurements is less than optimum for management of diabetes. | 03-20-2014 |
20140083867 | METHOD AND SYSTEM TO DERIVE MULTIPLE GLYCEMIC PATTERNS FROM GLUCOSE MEASUREMENTS DURING TIME OF THE DAY - Described are methods and systems for determining modal patterns from an overall trend, minor trend or significant trend for various periods during a time of the day modal report which can be utilized to provide insights to the person with diabetes. | 03-27-2014 |
20150100038 | METHOD AND SYSTEM FOR CONTROLLING A TUNING FACTOR DUE TO SENSOR REPLACEMENT FOR CLOSED-LOOP CONTROLLER IN AN ARTIFICIAL PANCREAS - Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed in the controller. The infusion pump is configured to deliver insulin. The glucose sensor senses glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor (R) for a model predictive controller in the microcontroller as a conservative setting otherwise the system maintains a current tuning factor (R) for the controller. | 04-09-2015 |
20160082187 | DECISIONS SUPPORT FOR PATIENTS WITH DIABETES - A decision support system includes a measurement device configured to continuously measure a physiological parameter of a patient. An insulin delivery device provides insulin to the patient per an initial basal profile and the parameter measurements. A storage device holds historical data of insulin delivery to the patient. A processor determines deviations of the delivery of insulin from the basal profile for one or more time period(s) using the historical data, computes a respective first basal-profile adjustment for each of the one or more time period(s) using the determined deviations, and annunciates the computed first basal-profile adjustment(s). A method of recommending a basal-rate adjustment includes measuring the parameter, infusing the patient with insulin and storing the historical data, determining the deviations from the basal profile, computing the first basal-profile adjustments, and annunciating the computed first basal-profile adjustment(s). | 03-24-2016 |